TRANSFORMING THE FUTURE OF CANCER TREATMENT

Your day–by–day guide to ASCO

4 – 8 June 2010

McCormick Place Convention Center
Chicago, Illinois, USA
Congress site plan

GATE 38
ROCHE bus transfer to the Investigator Meetings

Lakeside Center
(East Building)

LEVEL 4
Lakeside Ballroom
E354
Rooms E450-461
Rooms E350-353
Rooms E260-272

LEVEL 3
Halls D1 & D2
Halls B1 & B2
(Entrance level for Halls C1 & C2)

LEVEL 2
Hall E
Halls C1 & C2
(Entrance level for Hall A & B)

LEVEL 1
Offices

SKY BRIDGE

LEVEL 3
Halls D1 & D2
Halls B1 & B2
(Entrance level for Halls C1 & C2)

LEVEL 4
Rooms N920-931
Rooms N120-140

LEVEL 5
Rooms S501-505
Rooms S401-406

LEVEL 4

GRAND CONCOURSE

LEVEL 2.5
Food Court/Restaurant
Gift Shop
Business Center
METRA Entrance

HOTEL

MARTIN LUTHER KING JR. DRIVE

CONFERENCE CENTER
(Rooms CC 10-CC 24)
& Parking Lot A

CERMAK ROAD
Key

Key to symbols used throughout the planner

A Avastin
H Herceptin
T T-DM1
P Pertuzumab
M MabThera
T Tarceva
X Xeloda
POSTER DISCUSSION SESSION

Session #172: Breast Cancer – Metastatic

Time: 08:00 — 12:00
Venue: E450b

A Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC). (A. Brufsky; Poster Board 10, Abstract #1021)

X A phase I/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T). (K. Miller, MD; Poster Board 1, Abstract #1012)

T Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy. (P. LoRusso, DO; Panel Board 5, Abstract #1016)

Session #174: Central Nervous System Tumors

Time: 08:00 — 12:00
Venue: S103

A Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM). (J. J. Vredenburgh; Poster Board 15, Abstract #2023)
ORAL ABSTRACT SESSION

Session #160: Lymphoma

Time: 13:00 — 16:00
Venue: E354a

Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy. (G. A. Salles; Abstract #8004)

Presentation time: 13:00

GENERAL POSTER SESSION

Session #193: Breast Cancer – Local-Regional and Adjuvant Therapy

Time: 14:00 — 18:00
Venue: S Hall A2

Efficacy of capecitabine (C)-based therapy in patients with firstline metastatic breast cancer (MBC) previously treated with adjuvant anthracyclines and taxanes. (F. Siedentopf; Poster Board 17H, Abstract #665)

First-line patterns of care and outcomes of HER2-positive breast cancer patients who progressed after receiving adjuvant trastuzumab in the outpatient community setting. (S. K. Gruschkus; Poster Board 20C, Abstract #684)

Session #194: Breast Cancer - Metastatic

Time: 14:00 — 18:00
Venue: S Hall A2

Risk of venous and arterial thromboembolic events in patients with metastatic breast cancer treated with bevacizumab:
A meta-analysis. (V. Calvo; Poster Board 22D, Abstract #1043)
Risk of gastrointestinal perforation in patients with metastatic breast cancer treated with bevacizumab: A meta-analysis. (N. Ramirez; Poster Board 29B, Abstract #1091)

Phase II study of bevacizumab (Bev) combined with weekly paclitaxel (wPac) as first-line therapy for Japanese patients (pts) with HER2-negative metastatic breast cancer (MBC). (N. Masuda; Poster Board 36F, Abstract #1121)

Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): Preliminary safety data from the CECOG phase III TURANDOT trial. (I. Lang; Poster Board 37C, Abstract #1126)

Impact of CNS metastases on treatment and survival in patients receiving trastuzumab for metastatic breast cancer (MBC). (R. Griffiths; Poster Board 25A, Abstract #1064)

Pertuzumab and trastuzumab: Exploratory biomarker correlations with clinical benefit in patients with metastatic HER2-positive breast cancer. (J. Cortes; Poster Board 25F, Abstract #1066)

Capecitabine/trastuzumab for the first-line treatment of patients with HER2-positive metastatic breast cancer (MBC). (A. Chan; Poster Board 38H, Abstract #1139)

**ORAL ABSTRACT SESSION**

**Session #147: Central Nervous System Tumors**

**Time:** 15:00 — 18:00  
**Venue:** S100b

Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. (T. Cloughesy, MD; Abstract #2008)

**Presentation time:** 17:15
**GENERAL POSTER SESSION**

**Session #207: Lung Cancer – Metastatic**

*Clinical outcomes (CO) for special populations of patients (pts) with advanced non-small cell lung cancer (NSCLC): Results from ARIES, a bevacizumab (BV) observational cohort study (OCS). (A. J. Wozniak; Poster Board 44E, Abstract #7618)*

*Biomarker analyses from a phase I study of pertuzumab combined with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC). (E. Felip; Poster Board 32B, Abstract #7540)*

**Preliminary results of randomized phase III study comparing efficacy and safety of first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR-activating mutations (OPTIMAL). (C. Zhou; Poster Board 38, Abstract #7575)**

**Session #199: Gastrointestinal (Colorectal) Cancer**

*Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic colorectal cancer (mCRC): Initial results from ARIES, a second BV observational cohort study (OCS). (T. S. Bekaii-Saab, MD; Poster Board 8F, Abstract #3595)*

**Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP). (A. L. Cohn; Poster Board 8G, Abstract #3596)*
Session #200: Gastrointestinal (Noncolorectal) Cancer

Time: 14:00 — 18:00
Venue: S Hall A2

(Q)-TWiST analysis of trastuzumab plus fluoropyrimidine/cisplatin (T-XP/FP) versus XP/FP alone as first-line therapy for advanced HER2-positive gastric cancer. (H. C. Chung; Poster Board 19C, Abstract #4048)

ORAL ABSTRACT SESSION

Session #150: Gastrointestinal (Colorectal) Cancer

Time: 09:30 — 12:30
Venue: E Hall D1

Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): The MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]). (J. Tabernero MD; Abstract #3501)

Presentation time: 09:30

Session #152: Genitourinary Cancer (Prostate)

Time: 09:30 — 12:30
Venue: E Hall D2

A randomized, double-blind, placebo controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castrate-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. (W. K. Kelly; Abstract #LBA4511)

Presentation time: 12:00
PLENARY SESSION

Session #143: Plenary Session including Science of Oncology Award and Lecture

Time: 13:00 – 16:00
Venue: N Hall B1

Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study. (R. A. Burger; Abstract #LBA1)

Presentation time: 13:45

CLINICAL SCIENCE SYMPOSIUM

Session: Breast Cancer

Time: 16:30 – 18:00
Venue: N Hall B1

Impact of treatment characteristics on response of different breast cancer subtypes: Pooled multilayer analysis of the German neoadjuvant chemotherapy trials. (G. Von Minckwitz; Abstract #501)

Presentation time: 17:00
**GENERAL POSTER SESSION**

Session #198: Developmental Therapeutics – Experimental Therapeutics

Time: 08:00 — 12:00  
Venue: S Hall A2

- Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). (H. Hurwitz; Poster Board 11A, Abstract #3039)

**TRIALS IN PROGRESS POSTER SESSION**

Session #273: Trials in Progress Poster Session

Time: 08:00 — 12:00  
Venue: S Hall A2

- ICE II: An investigational randomized phase II study on epirubicin (E) plus cyclophosphamide (C) (or CMF) versus nab-paclitaxel plus capecitabine (PX) as adjuvant chemotherapy for elderly nonfrail patients with an increased risk for relapse of a primary carcinoma of the breast.  
  (G. Von Minckwitz; Poster Board 21A, Abstract #TPS104)

**POSTER DISCUSSION SESSION**

Session #186: Lung Cancer – Metastatic

Time: 08:00 — 12:00  
Venue: E450b

- Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with b for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). (F. F. Kabbinavar; Poster Board 15, Abstract #7526)
Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial. (L. Vamvakas; Poster Board 8, Abstract #7519)

Session #171: Breast Cancer - Local-Regional and Adjuvant Therapy

Pathologic complete response (pCR) in patient subgroups: An analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC). (G. G. Steger; Poster Board 18, Abstract #530)

Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): Efficacy in patients with triple-negative breast cancer (BC). (H. Joensuu, MD; Poster Board 19, Abstract #531)

ORAL ABSTRACT SESSION

Session #151: Gastrointestinal (Noncolorectal) Cancer

AVAGAST: a randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin + bevacizumab or placebo in patients with advanced gastric cancer (AGC). (Y-K. Kang; Abstract #LBA4007)

Presentation time: 15:45
Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. (P. A. Janne, Abstract #7503)

Presentation time: 15:00

Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. (M. PerolAbstract #7507)

Presentation time: 16:00
POSTER DISCUSSION SESSION

Session # 177: Gastrointestinal (Colorectal) Cancer

Time: 08:00 — 12:00
Venue: S403

Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): No impact of age on disease-free survival (DFS). (D. G. Haller; Poster Board 13, Abstract #3521)

ORAL ABSTRACT SESSION

Session #145: Breast Cancer – Metastatic

Time: 09:30 — 12:30
Venue: E Hall D1

A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). (J. O’Shaughnessy; Abstract #1005)

Presentation time: 10:45

Session #153: Genitourinary Cancer (Testes, Kidney, and Bladder)

Time: 09:30 — 12:30
Venue: E Arie Crown Theater

A Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial. (B. J. Escudier; Abstract #4516)

Presentation time: 10:45

13 Avastin Herceptin T-DM1 Pertuzumab
Hotels

**Hilton Chicago**
720 South Michigan Avenue  
Chicago, 60605 IL  
Tel: +1 312 922 4400  
Tel: +1 312 922 5240  
*Breakfast: Restaurant Pavilion*  
Mon-Fri 06:00 — 11:00  
Sat-Sun 06:00 — 12:00

**Palmer House Hilton**
17 East Monroe Street  
Chicago, IL 60603  
Tel: +1 312 726 7500  
*Breakfast: Exhibit Hall*  
06:30 — 10:30

**W Lake Shore**
644 North Lake Shore Drive  
Chicago, IL 60611  
Tel: +1 312 943 9200  
*Breakfast: ALTITUDE, 33rd Floor*  
06:30 — 10:30

**Conrad Hilton**
521 North Rush Street  
Chicago, IL 60611  
Tel: +1 312 645 1500  
*Breakfast: Restaurant at Conrad*  
06:30 — 10:30

**Crowne Plaza Metro**
733 West Madison Street  
Chicago, IL 60661  
Tel: +1 312 829 5000  
*Breakfast: Restaurant Dine*  
06:00 — 10:00
Hotels

The Drake
140 East Walton Place
Chicago, IL 60611-1501
Tel: +1 312 787 2200
Fax: +1 312 787 1431
Breakfast: Drake Bros’ Restaurant
06:30 — 11:30

Renaissance Blackstone Chicago Hotel
636 South Michigan Avenue
Chicago, IL 60605
Tel: +1 312 447 0955
Fax: +1 312 765 0545
Breakfast: Restaurant Mercat
Mon-Fri 06:30 — 11:00
Sat-Sun 07:00 — 11:00

Sheraton Chicago Hotel & Towers
301 East North Water Street
Chicago, IL 60611
Tel: +1 312 464 1000
Fax: +1 312 464 9140
Breakfast: LB Bistro and Patisserie
Mon-Sun 06:30 — 11:30